Introduction
The risk oftumor formation from exposure to a chemical carcinogen is dependent on the exposure, the potency of the carcinogen, and the individual host reaction. Humans are exposed to chemical carcinogens at dose levels which are orders of magnitude below the levels used in animal studies on carcinogenicity. The latter experiments provide significant data only at high-dose levels which lead to tumor incidences on the order of percent ( Fig. 1 ). For humans, tolerable exposures producing not more than one additional tumor in one million lives should be defined. The extrapolation range therefore covers four to five orders of magnitude. Instead of using purely mathematical models for the extrapolation, it would be desirable to have a biologically relevant indicator which could be investigated in the dose range to be bridged.
A large group of chemical carcinogens is known to bind covalently to DNA in the target cell. Under appropriate conditions, this primary DNA lesion can be expressed as a mutation finally leading to cancer. The primary interaction of the carcinogen with DNA can be investigated with appropriate techniques (radiolabeled test compound, phosphorylation with 32p, or immunological methods) at low dose levels which would not give rise to a detectable increase in tumor yield with a limited number of animals treated. It is therefore possible to investigate the shape of the dose-response curve in the region of interest.
Methods
With radiolabeled test compound, the limit of detection is dependent on the specific activity, on the binding potency (covalent binding index, CBI; Lutz 1979), on the amount of DNA analyzed, and on the radioactivity in a vial considered significant. Under optimal conditions met, for instance, with tritiated aflatoxin Bl of8 Ci/mmol and a CBI of10000, a single dose of1 ng/kg rat was the observed limit of detection for liver DNA binding (10 dpm net radioactivity in 6 mg DNA). For formaldehyde (FA) and vinyl chloride (VC) exposure was by inhalation, 6 h/day, 5 days/week, for 2 years; the top dose scale applies. The two scales were combined on the assumption of a respiratory minute volume of 750 m1 air/kg and an absorption of 20% This corresponded to 3 adducts per 10 11 nuc1eotides, i.e., less than 1 adduct per liver cell genome. With 14C-Iabeled compounds of 10 mCi/mmol, the limit of detection would have been about 500 times higher, i.e., 1 adduct in 10 8 nuc1eotides. A model calculation for the postlabeling technique using HPLC methods gives the following results: With [y_ 32 p]ATP of a specific activity of 1000 Ci/mmol, an assumed limit of detection of 20 dpm would correspond to 0.01 fmol adduct, i.e., a level of 3 in 10 9 nuc1eotides in a l-llg DNA sample.
DNA-Binding at Low Doses
With antibodies and the slot-blot technique (Rajewsky, personal communication), 0.1 fmol adduct can be detected in 3 Ilg DNA. This corresponds to an adduct level of 1 in 10 8 nuc1eotides.
A comparison of the three methods therefore shows that for the testing of new compounds, and where only small amounts of DNA are available from a specific tissue, the postlabeling technique seems most versatile.
